REVELUTION-2 trial assesses cardiovascular safety of relugolix plus abiraterone in high‑risk prostate cancer
The REVELUTION-2 study is focused on measuring the heart‑related risks associated with a hormone‑therapy regimen that combines relugolix and abiraterone acetate in patients with high‑risk prostate cancer.
Dr. Sagar A. Patel, MD, provided an overview of the trial design and its objectives, emphasizing the importance of understanding cardiovascular outcomes when using this combination therapy.
The investigation targets a population at elevated risk for both cancer progression and cardiovascular events, aiming to generate data that could guide treatment decisions and safety monitoring.
Results have not yet been released, and the trial continues to enroll participants while monitoring safety endpoints.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer”
read at onclive ↗
comments(0)
5-min edit window · permanent after that